Yang Liu

Dr. Yang Liu


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2008 in BMC Neuroscience
Verified
Journal Article
Open access
PDF file
ESEveline H Shue
Eveline H Shue
ECEleanor B Carson-Walter
Eleanor B Carson-Walter
YLYang Liu
Yang Liu
BWBethany N Winans
Bethany N Winans
ZAZarina S Ali
Zarina S Ali
KWKevin A Walter
Kevin A Walter
Background: Plasmalemmal vesicle associated protein-1 (PV-1) is selectively expressed in human brain microvascular endothelial cells derived from clinical specimens of primary and secondary malignant brain tumors, cerebral ischemia, and other central nervous system (CNS) diseases associated with blood-brain barrier breakdown. In this study, we characterize the murine CNS expression pattern of PV-1 to determine whether localized PV-1 induction is conserved across species and disease state. Results: We demonstrate that PV-1 is selectively upregulated in mouse blood vessels recruited by brain tumor xenografts at the RNA and protein levels, but is not detected in non-neoplastic brain. Additionally, PV-1 is induced in a mouse model of acute ischemia. Expression is confined to the cerebovasculature within the region of infarct and is temporally regulated. Conclusion: Our results confirm that PV-1 is preferentially induced in the endothelium of mouse brain tumors and acute ischemic brain tissue and corresponds to blood-brain barrier disruption in a fashion analogous to human patients. Characterization of PV-1 expression in mouse brain is the first step towards development of rodent models for testing anti-edema and anti-angiogenesis therapeutic strategies based on this molecule.

30 November 2009 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ECEleanor B Carson-Walter
Eleanor B Carson-Walter
BWBethany N Winans
Bethany N Winans
MWMelissa C Whiteman
Melissa C Whiteman
YLYang Liu
Yang Liu
SJSally Jarvela
Sally Jarvela
KWKevin A Walter
Kevin A Walter
TEM1/endosialin is an emerging microvascular marker of tumor angiogenesis. We characterized the expression pattern of TEM1/endosialin in astrocytic and metastatic brain tumors and investigated its role as a therapeutic target in human endothelial cells and mouse xenograft models.

28 September 2020 in Anticancer Research
Verified
Journal Article
Closed access
PDF file
YLYang Liu
Yang Liu
MSMyla S. Strawderman
Myla S. Strawderman
KWKwanza T. Warren
Kwanza T. Warren
MRMargie Richardson
Margie Richardson
JSJennifer N. Serventi
Jennifer N. Serventi
KWKevin A Walter
Kevin A Walter
Background/Aim: Whether adding tumor treating fields (TTF) to the Stupp protocol increases survival for glioblastoma (GBM) patients in routine clinical care remains unknown. Patients and Methods: We retrospectively identified adult patients with newly diagnosed GBM (n=104) treated with the Stupp protocol or TTF at our Institution. Results: Thirty-six percent (37/104) of patients received TTF in conjunction with the Stupp protocol and these patients had increased 6-month (p=0.006) and 1-year (p=0.170), but not 2-year survival rates compared to the 67-patients who received Stupp alone. The improvement of survival rate at 6-month was further confirmed by a modified Poisson model (p=0.010). However, we did not observe any improvement in overall survival (OS) with a Cox model. Conclusion: While adding TTF to the Stupp protocol appeared to benefit patients with newly diagnosed GBM, this effect was mild and may be largely due to selection bias.

1 August 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
ECEleanor Carson-Walter
Eleanor Carson-Walter
KWKevin A Walter
Kevin A Walter
The chemokine CXCL12 regulates multiple cell functions through its receptor, CXCR4. However, recent studies have shown that CXCL12 also binds a second receptor, CXCR7, to potentiate signal transduction and cell activity. In contrast to CXCL12/CXCR4, few studies have focused on the role of CXCR7 in vascular biology and its role in human brain microvascular endothelial cells (HBMECs) remains unclear. In this report, we used complementary methods, including immunocytofluorescence, Western blot, and flow cytometry analyses, to demonstrate that CXCR7 was expressed on HBMECs. We then employed short hairpin RNA (shRNA) technology to knockdown CXCR7 in HBMECs. Knockdown of CXCR7 in HBMECs resulted in significantly reduced HBMEC proliferation, tube formation, and migration, as well as adhesion to matrigel and tumor cells. Blocking CXCR7 with a specific antibody or small molecule antagonist similarly disrupted HBMEC binding to matrigel or tumor cells. We found that tumor necrosis factor (TNF)-α induced CXCR7 in a time and dose-response manner and that this increase preceded an increase in vascular cell adhesion molecule-1 (VCAM-1). Knockdown of CXCR7 resulted in suppression of VCAM-1, suggesting that the reduced binding of CXCR7-knockdown HBMECs may result from suppression of VCAM-1. Collectively, CXCR7 acted as a functional receptor for CXCL12 in brain endothelial cells. Targeting CXCR7 in tumor vasculature may provide novel opportunities for improving brain tumor therapy.

1 January 2015
Verified
Journal Article
Closed access
YLYang Liu
Yang Liu
ECEleanor Carson-Walter
Eleanor Carson-Walter
KWKevin A Walter
Kevin A Walter

6 March 2019 in Anticancer Research
Verified
Journal Article
Open access
PDF file
YLYang Liu
Yang Liu
ETEvan Tyler
Evan Tyler
MLMartin Lustick
Martin Lustick
DKDavid Klein
David Klein
KWKevin A Walter
Kevin A Walter
Background/Aim: Data on verified healthcare costs for high-grade gliomas (HGGs) are limited. This study aimed to determine the healthcare costs for HGGs. Materials and Methods: A total of 88 primary HGGs patients diagnosed and treated at our Institution between 2011 and 2017 who had insurance plans administered with Excellus BCBS were retrospectively identified. Patient clinical information was linked with all verified insurance payment data. Results: Median insurance payments for clinical management of HGGs were $184,159.83. The leading cost was therapeutic radiation oncology. Patients under commercial insurance had a longer survival time, and higher healthcare expenditures in total and in each phase of clinical care. Healthcare costs were higher during therapy initiation and at disease recurrence and lower during the interim. A generalized linear model showed that patients with commercial insurance, better Karnofsky Performance Status, and longer survival time had higher healthcare expenditures. Conclusion: Healthcare payments for HGGs patients were substantial and such high healthcare expenditures were positively associated with patient survival and commercial insurance.